Irina Alafuzoff

List of Publications by Year
in descending order

106 papers	12,354 citations	81900 39 h-index	30087 103 g-index
110 all docs	110 docs citations	110 times ranked	13690 citing authors

#	Article	IF	Citations
1	Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathologica, 2006, 112, 389-404.	7.7	2,318
2	Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature. Journal of Neuropathology and Experimental Neurology, 2012, 71, 362-381.	1.7	1,599
3	Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathologica, 2014, 128, 755-766.	7.7	1,060
4	Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain, 2019, 142, 1503-1527.	7.6	873
5	Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathologica, 2010, 119, 1-4.	7.7	854
6	Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathologica, 2016, 131, 87-102.	7.7	380
7	Staging of Neurofibrillary Pathology in Alzheimer's Disease: A Study of the BrainNet Europe Consortium. Brain Pathology, 2008, 18, 484-496.	4.1	361
8	Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies. NeuroReport, 2001, 12, 2085-2090.	1.2	316
9	Applicability of current staging/categorization of Î±-synuclein pathology and their clinical relevance. Acta Neuropathologica, 2008, 115, 399-407.	7.7	294
10	Î±â€Synuclein pathology does not predict extrapyramidal symptoms or dementia. Annals of Neurology, 2005, 57, 82-91.	5.3	287
11	Staging/typing of Lewy body related Î±-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathologica, 2009, 117, 635-652.	7.7	249
12	Morphogenesis of Lewy Bodies: Dissimilar Incorporation of Î±-Synuclein, Ubiquitin, and p62. Journal of Neuropathology and Experimental Neurology, 2003, 62, 1241-1253.	1.7	240
13	The Human Glioblastoma Cell Culture Resource: Validated Cell Models Representing All Molecular Subtypes. EBioMedicine, 2015, 2, 1351-1363.	6.1	228
14	Altered Proteins in the Aging Brain. Journal of Neuropathology and Experimental Neurology, 2016, 75, 316-325.	1.7	153
15	Mixed Brain Pathologies in Dementia: The BrainNet Europe Consortium Experience. Dementia and Geriatric Cognitive Disorders, 2008, 26, 343-350.	1.5	148
16	Assessment of Î²-amyloid deposits in human brain: a study of the BrainNet Europe Consortium. Acta Neuropathologica, 2009, 117, 309-320.	7.7	143
17	An antibody with high reactivity for disease-associated Î±-synuclein reveals extensive brain pathology. Acta Neuropathologica, 2012, 124, 37-50.	7.7	133
18	Poor Cognitive Outcome in Shunt-Responsive Idiopathic Normal Pressure Hydrocephalus. Neurosurgery, 2013, 72, 1-8.	1.1	129

#	Article	IF	Citations
19	Amyloid and tau proteins in cortical brain biopsy and Alzheimer's disease. Annals of Neurology, 2010, 68, 446-453.	5.3	128
20	Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium. Acta Neuropathologica, 2008, 115, 497-507.	7.7	101
21	Post-mortem assessment in vascular dementia: advances and aspirations. BMC Medicine, 2016, 14, 129.	5.5	99
22	Interlaboratory Comparison of Assessments of Alzheimer Disease-Related Lesions: A Study of the BrainNet Europe Consortium. Journal of Neuropathology and Experimental Neurology, 2006, 65, 740-757.	1.7	95
23	Cerebrospinal Fluid Biomarker and Brain Biopsy Findings in Idiopathic Normal Pressure Hydrocephalus. PLoS ONE, 2014, 9, e91974.	2.5	91
24	Inter-laboratory comparison of neuropathological assessments of Î²-amyloid protein: a study of the BrainNet Europe consortium. Acta Neuropathologica, 2008, 115, 533-546.	7.7	86
25	Postmortem Examination of Vascular Lesions in Cognitive Impairment. Stroke, 2006, 37, 1005-1009.	2.0	82
26	Hyperphosphorylated tau in young and middle-aged subjects. Acta Neuropathologica, 2012, 123, 97-104.	7.7	82
27	Neuropathologic Features of Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions Visualized With Ubiquitin-Binding Protein p62 Immunohistochemistry. Journal of Neuropathology and Experimental Neurology, 2008, 67, 280-298.	1.7	76
28	Assessment of Î±-Synuclein Pathology: A Study of the BrainNet Europe Consortium. Journal of Neuropathology and Experimental Neurology, 2008, 67, 125-143.	1.7	73
29	Widespread and abundant Î±â€synuclein pathology in a neurologically unimpaired subject. Neuropathology, 2005, 25, 304-314.	1.2	71
30	Extension of diffuse low-grade gliomas beyond radiological borders as shown by the coregistration of histopathological and magnetic resonance imaging data. Journal of Neurosurgery, 2016, 125, 1155-1166.	1.6	58
31	The need to unify neuropathological assessments of vascular alterations in the ageing brain. Experimental Gerontology, 2012, 47, 825-833.	2.8	57
32	Subtyping of gliomas of various <scp>WHO</scp> grades by the application of immunohistochemistry. Histopathology, 2014, 64, 365-379.	2.9	56
33	Transcriptomics and mechanistic elucidation of Alzheimer's disease risk genes in the brain and inÂvitro models. Neurobiology of Aging, 2015, 36, 1221.e15-1221.e28.	3.1	55
34	U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden. Acta OncolÃ³gica, 2018, 57, 187-194.	1.8	52
35	Human Traumatic Brain Injury Results in Oligodendrocyte Death and Increases the Number of Oligodendrocyte Progenitor Cells. Journal of Neuropathology and Experimental Neurology, 2016, 75, 503-515.	1.7	51
36	Alpha-synucleinopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 145, 339-353.	1.8	50

#	Article	IF	Citations
37	The Effect of Prolonged Fixation Time on Immunohistochemical Staining of Common Neurodegenerative Disease Markers. Journal of Neuropathology and Experimental Neurology, 2010, 69, 40-52.	1.7	49
38	Correlations Between Mini-Mental State Examination Score, Cerebrospinal Fluid Biomarkers, and Pathology Observed in Brain Biopsies of Patients With Normal-Pressure Hydrocephalus. Journal of Neuropathology and Experimental Neurology, 2015, 74, 470-479.	1.7	48
39	Glioblastoma Cell Malignancy and Drug Sensitivity Are Affected by the Cell of Origin. Cell Reports, 2017, 18, 977-990.	6.4	46
40	Lower Counts of Astroglia and Activated Microglia in Patients with Alzheimer's Disease with Regular Use of Non-Steroidal Anti-Inflammatory Drugs. Journal of Alzheimer's Disease, 2000, 2, 37-46.	2.6	41
41	Severity of Cardiovascular Disease, Apolipoprotein E Genotype, and Brain Pathology in Aging and Dementia. Annals of the New York Academy of Sciences, 2000, 903, 244-251.	3.8	39
42	Amyloid-Î² and Tau Dynamics in Human Brain Interstitial Fluid in Patients with Suspected Normal Pressure Hydrocephalus. Journal of Alzheimer's Disease, 2015, 46, 261-269.	2.6	39
43	Multisite Assessment of Aging-Related Tau Astrogliopathy (ARTAG). Journal of Neuropathology and Experimental Neurology, 2017, 76, 605-619.	1.7	38
44	Incidence, Comorbidities, and Mortality in Idiopathic Normal PressureÂHydrocephalus. World Neurosurgery, 2018, 112, e624-e631.	1.3	37
45	Human Cytomegalovirus Tegument Protein pp65 Is Detected in All Intra- and Extra-Axial Brain Tumours Independent of the Tumour Type or Grade. PLoS ONE, 2014, 9, e108861.	2.5	37
46	Diffusion kurtosis imaging of gliomas grades II and III - a study of perilesional tumor infiltration, tumor grades and subtypes at clinical presentation. Radiology and Oncology, 2017, 51, 121-129.	1.7	37
47	High Risk of Dementia in Ventricular Enlargement with Normal Pressure Hydrocephalus Related Symptoms1. Journal of Alzheimer's Disease, 2016, 52, 497-507.	2.6	36
48	Characteristics of the tissue section that influence the staining outcome in immunohistochemistry. Histochemistry and Cell Biology, 2019, 151, 91-96.	1.7	29
49	Targeting coagulation factor XII as a novel therapeutic option in brain trauma. Annals of Neurology, 2016, 79, 970-982.	5.3	28
50	Predicting Development of Alzheimerâ€™s Disease in Patients with Shunted Idiopathic Normal Pressure Hydrocephalus. Journal of Alzheimer's Disease, 2019, 71, 1233-1243.	2.6	28
51	New lexicon and criteria for the diagnosis of Alzheimer's disease. Lancet Neurology, The, 2011, 10, 298-299.	10.2	26
52	Neuropathological assessments of the pathology in frontotemporal lobar degeneration with TDP43-positive inclusions: an inter-laboratory study by the BrainNet Europe consortium. Journal of Neural Transmission, 2015, 122, 957-972.	2.8	25
53	Brain tissue AÎ²42 levels are linked to shunt response in idiopathic normal pressure hydrocephalus. Journal of Neurosurgery, 2018, 130, 121-129.	1.6	25
54	Slowly progressive dementia caused by MAPT R406W mutations: longitudinal report on a new kindred and systematic review. Alzheimer's Research and Therapy, 2018, 10, 2.	6.2	25

#	Article	IF	Citations
55	TAR-DNA binding protein-43 and alterations in the hippocampus. Journal of Neural Transmission, 2011, 118, 683-689.	2.8	24
56	Upregulated expression of Fas and Fas ligand in brain through the spectrum of HIV-1 infection. Acta Neuropathologica, 1999, 98, 355-362.	7.7	23
57	Systematic Appraisal Using Immunohistochemistry of Brain Pathology in Aged and Demented Subjects. Dementia and Geriatric Cognitive Disorders, 2008, 25, 423-432.	1.5	23
58	APOE4 predicts amyloid-Î² in cortical brain biopsy but not idiopathic normal pressure hydrocephalus. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 1119-1124.	1.9	23
59	Modeling SHH-driven medulloblastoma with patient iPS cell-derived neural stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 20127-20138.	7.1	23
60	The Uppsala APP deletion causes early onset autosomal dominant Alzheimerâ€™s disease by altering APP processing and increasing amyloid Î² fibril formation. Science Translational Medicine, 2021, 13, .	12.4	23
61	Interleukin-18 alters protein expressions of neurodegenerative diseases-linked proteins in human SH-SY5Y neuron-like cells. Frontiers in Cellular Neuroscience, 2014, 8, 214.	3.7	22
62	Multimodal analysis to predict shunt surgery outcome of 284 patients with suspected idiopathic normal pressure hydrocephalus. Acta Neurochirurgica, 2016, 158, 2311-2319.	1.7	21
63	Does protein expression predict recurrence of benign World Health Organization grade I meningioma?. Human Pathology, 2010, 41, 199-207.	2.0	19
64	The Expression of Transthyretin and Amyloid-Î² Protein Precursor is Altered in the Brain of Idiopathic Normal Pressure Hydrocephalus Patients. Journal of Alzheimer's Disease, 2015, 48, 959-968.	2.6	19
65	Human Postmortem Brain Tissue and 2-mm Tissue Microarrays. Applied Immunohistochemistry and Molecular Morphology, 2006, 14, 353-359.	1.2	18
66	Ubiquitinated p62-positive, TDP-43-negative inclusions in cerebellum in frontotemporal lobar degeneration with TAR DNA binding protein 43. Neuropathology, 2010, 30, 197-199.	1.2	18
67	Beer Drinking Associates with Lower Burden of Amyloid Beta Aggregation in the Brain: Helsinki Sudden Death Series. Alcoholism: Clinical and Experimental Research, 2016, 40, 1473-1478.	2.4	18
68	Epilepsy in neuropathologically verified Alzheimerâ€™s disease. Seizure: the Journal of the British Epilepsy Association, 2018, 58, 9-12.	2.0	17
69	Cause of death and significant disease found at autopsy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 781-788.	2.8	17
70	Oncogene-Induced Senescence in Pituitary Adenomasâ€”an Immunohistochemical Study. Endocrine Pathology, 2016, 27, 1-11.	9.0	16
71	Mouse Models of Pediatric Supratentorial High-grade Glioma Reveal How Cell-of-Origin Influences Tumor Development and Phenotype. Cancer Research, 2017, 77, 802-812.	0.9	15
72	Detection of Changes in Immunohistochemical Stains Caused by Postmortem Delay and Fixation Time. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 238-245.	1.2	15

#	Article	IF	Citations
73	Alzheimerâ€™s disease neuropathological change and loss of matrix/neuropil in patients with idiopathic Normal Pressure Hydrocephalus, a model of Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2019, 7, 98.	5.2	15
74	Pleiotrophin enhances PDGFB-induced gliomagenesis through increased proliferation of neural progenitor cells. Oncotarget, 2016, 7, 80382-80390.	1.8	15
75	Pitfalls in the quantitative estimation of Î²-amyloid immunoreactivity in human brain tissue. Histochemistry and Cell Biology, 1998, 110, 439-445.	1.7	14
76	Long-term memory performance after surgical treatment of unilateral temporal lobe epilepsy (TLE). Epilepsy Research, 2014, 108, 1228-1237.	1.6	14
77	Accumulation of alpha-synuclein within the liver, potential role in the clearance of brain pathology associated with Parkinsonâ€™s disease. Acta Neuropathologica Communications, 2021, 9, 46.	5.2	14
78	[11C]PIB PET Is Associated with the Brain Biopsy Amyloid-Î² Load in Subjects Examined for Normal Pressure Hydrocephalus. Journal of Alzheimer's Disease, 2019, 67, 1343-1351.	2.6	13
79	Using the Disease State Fingerprint Tool for Differential Diagnosis of Frontotemporal Dementia and Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2016, 6, 313-329.	1.3	12
80	Increased Î³-Secretase Activity in Idiopathic Normal Pressure Hydrocephalus Patients with Î²-Amyloid Pathology. PLoS ONE, 2014, 9, e93717.	2.5	12
81	Distribution and Pattern of Pathology in Subjects with Familial or Sporadic Late-Onset Cerebellar Ataxia as Assessed by p62/Sequestosome Immunohistochemistry. Cerebellum, 2011, 10, 720-731.	2.5	11
82	Staged pathology in Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, S57-S61.	2.2	11
83	Prognostic markers for survival in patients with oligodendroglial tumors; a single-institution review of 214 cases. PLoS ONE, 2017, 12, e0188419.	2.5	11
84	The value of magnetic resonance spectroscopy as a supplement to MRI of the brain in a clinical setting. PLoS ONE, 2018, 13, e0207336.	2.5	11
85	Mast Cell Infiltration in Human Brain Metastases Modulates the Microenvironment and Contributes to the Metastatic Potential. Frontiers in Oncology, 2017, 7, 115.	2.8	10
86	Mixed Brain Pathology Is the Most Common Cause of Cognitive Impairment in the Elderly. Journal of Alzheimer's Disease, 2020, 78, 453-465.	2.6	10
87	Alzheimer's diseaseâ€related plaques in nondemented subjects. Alzheimer's and Dementia, 2014, 10, 522-529.	0.8	8
88	Progression of Alzheimerâ€™s Disease-Related Pathology and Cell Counts in a Patient with Idiopathic Normal Pressure Hydrocephalus. Journal of Alzheimer's Disease, 2018, 61, 1451-1462.	2.6	8
89	Minimal neuropathologic diagnosis for brain banking in the normal middle-aged and aged brain and in neurodegenerative disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 150, 131-141.	1.8	8
90	Transactive DNA Binding Protein 43 Rather Than Other Misfolded Proteins in the Brain is Associated with Islet Amyloid Polypeptide in Pancreas in Aged Subjects with Diabetes Mellitus. Journal of Alzheimer's Disease, 2017, 59, 43-56.	2.6	7

#	Article	IF	Citations
91	Preoperative Quantitative MR Tractography Compared with Visual Tract Evaluation in Patients with Neuropathologically Confirmed Gliomas Grades II and III: A Prospective Cohort Study. Radiology Research and Practice, 2016, 2016, 1-15.	1.3	6
92	Effects of Alzheimerâ€™s Disease-Associated Risk Loci on Amyloid-Î² Accumulation in the Brain of Idiopathic Normal Pressure Hydrocephalus Patients. Journal of Alzheimer's Disease, 2016, 55, 995-1003.	2.6	6
93	Comorbidities. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 145, 573-577.	1.8	4
94	Alzheimer's Disease-Related Lesions. Journal of Alzheimer's Disease, 2012, 33, S173-S179.	2.6	4
95	Novel amplifications in pediatric medulloblastoma identified by genome-wide copy number profiling. Journal of Neuro-Oncology, 2012, 107, 37-49.	2.9	3
96	In vivo Characterization of Biochemical Variants of Amyloid-Î² in Subjects with Idiopathic Normal Pressure Hydrocephalus and Alzheimerâ€™s Disease Neuropathological Change. Journal of Alzheimer's Disease, 2021, 80, 1003-1012.	2.6	3
97	Atypical Huntingtonâ€™s disease with the clinical presentation of behavioural variant of frontotemporal dementia. Journal of Neural Transmission, 2016, 123, 1423-1433.	2.8	2
98	Techniques in neuropathology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 145, 3-7.	1.8	2
99	Unusual clinical presentation and neuropathology in two subjects with fusedâ€in sarcoma (FUS) positive inclusions. Neuropathology, 2012, 32, 60-68.	1.2	1
100	To Stage Alzheimerâ€™s Disease Related Neurodegeneration Using one Section ofÂHippocampus. Journal of Alzheimer's Disease, 2015, 48, 597-601.	2.6	1
101	Mechanical reperfusion with leucocyte-filtered blood does not prevent injury following global cerebral ischaemia. European Journal of Cardio-thoracic Surgery, 2016, 51, ezw367.	1.4	1
102	Expression of CMV protein pp65 in cutaneous malignant melanoma. PLoS ONE, 2019, 14, e0223854.	2.5	1
103	Gastrointestinal Biopsy Obtained During Cancer Screening, a Biological Marker for Î±-Synucleinopathy?. Journal of Neuropathology and Experimental Neurology, 2022, 81, 356-362.	1.7	1
104	O1-01-01: Cerebrospinal fluid biomarkers for Alzheimer's disease are associated with neuropathology in cortical brain biopsy. , 2012, 8, P83-P84.		0
105	F2â€04â€01: NEUROPATHOLOGY OF VCID: A CLASSICAL LANDSCAPE. Alzheimer's and Dementia, 2019, 15, P521.	0.8	0
106	Synucleinopathies. , 2014, , 149-175.		0